Featured Research

from universities, journals, and other organizations

Melanoma stem cells' evasive talents

Date:
January 13, 2010
Source:
Children's Hospital Boston
Summary:
Melanoma, if not detected in its early stages, transforms into a highly deadly, treatment-resistant cancer. Although the immune system initially responds to melanoma and mounts anti-tumor attacks, these assaults are generally ineffective, allowing more advanced melanomas to win the battle and spread beyond the primary site. Now, researchers shed light on how melanomas stimulate, yet ultimately evade, a patient's immune system.

Melanoma, if not detected in its early stages, transforms into a highly deadly, treatment-resistant cancer. Although the immune system initially responds to melanoma and mounts anti-tumor attacks, these assaults are generally ineffective, allowing more advanced melanomas to win the battle and spread beyond the primary site. Now, researchers at Children's Hospital Boston and Brigham and Women's Hospital (BWH) shed light on how melanomas stimulate, yet ultimately evade, a patient's immune system. Their work, published online January 12 by the journal Cancer Research, also suggests ways drugs might block these tactics.

In 2008, the same team, led by Markus Frank, MD, of the Transplantation Research Center of Children's and BWH, and George Murphy, MD, chief of Dermatopathology at BWH, showed in the journal Nature that a key reason for melanoma virulence is a small group of tumor stem cells that are able to grow despite chemotherapy drugs, allowing the tumor to re-grow and progress. They also showed that targeting these cells (identifiable by a molecule on their surface known as ABCB5) could successfully inhibit tumor growth in mice. (The ABCB5 technology has been licensed and is currently in clinical drug development.)

In their new paper, first author Tobias Schatton, PhD, of the Transplantation Research Center, and colleagues show that these ABCB5-positive cells also produce molecules that inhibit the body's natural immune attack, known as PD-1 and B7.2. These molecules work, they found, by triggering white blood cells known as regulatory T cells (T-regs), to dampen the normal anti-melanoma response. The T-regs are thus tricked into protecting the deadly melanoma stem cells from the body's own defenses.

"To my knowledge, this study provides the first evidence that cancer stem cells escape and down-regulate host antitumor immunity," says Frank, the study's senior investigator, also affiliated with the Department of Dermatology at BWH. "This might have important implications for cancer therapy, especially in malignant melanoma."

Additional experiments showed that melanoma stem cells stimulate surrounding cells' production of IL-10, a signaling molecule that suppresses the immune system, and inhibit production of IL-2, which stimulates immune attack. The melanoma stem cells also produce fewer of the antigens that trigger immune responses, further evading immune attack.

The study adds to a growing body of evidence that melanoma stem cells have developed a repertoire of complementary strategies to outsmart host defenses, camouflaging them from the very immune cells and therapeutic agents that seek to destroy them. It also suggests new strategies for attacking the deadly skin cancer.

"Melanoma stem cell targeting holds promise for an absolute cure, because you're hitting the cells that really matter -- the cells that drive tumor progression," says Murphy. "By understanding the precise molecular pathways whereby melanoma stem cells cajole the immune system into a permissive role, scientists are now closer to identifying ways of blocking or inhibiting such tactics."

For example, inhibition of PD-1 and B7.2 on melanoma stem cells could render them vulnerable not only to immune defenses, but also to treatments that are currently only effective against the more susceptible non-stem cell component of the tumor. Stripping away the stem cells' "protective shield" may allow a tumor to be killed without the possibility of it re-growing.

Melanomas are highly immunogenic cancers, initially provoking anti-tumor attacks, as evidenced by patients whose brown-black skin tumors seem to have partly dissolved away, producing regions of pink to white coloration where pigment previously existed. But ultimately, melanomas evade the immune system; until now, how the key cells that drive the melanomas' growth accomplish this has been a mystery.

The current work is relevant primarily to metastatic melanoma, which is often incurable, says Murphy. In their early, flat stages, melanomas can be cured surgically, but are potentially deadly once they grow as a skin elevation (sometimes no larger than a small pea) and spread to lymph nodes or vital organs. Scientists have long sought to find ways to target and destroy melanoma deposits that have already spread.

The research team is now planning to examine the ability of currently approved or investigational immunotherapeutic strategies to target and inhibit the immune-evasion tactics and immunological tolerance induced by melanoma stem cells. Specifically, they hope to participate in several ongoing or future clinical trials that target specific immunologic signaling pathways in melanoma patients (using anti-PD-1 antibodies, for example), to track the response of ABCB5-positive melanoma stem cells.

The study was funded by the National Cancer Institute. Coauthors were: Ute Schutte, Andre Hoerning and Susanne Robles, of the Transplantation Research Center, Children's Hospital Boston and BWH; Natasha Frank, of BWH and the VA Boston Healthcare System; Qian Zhan of BWH; Jun Zhou and F. Stephen Hodi of the Dana-Farber Cancer Institute; and Giulio Spagnoli of University Hospital Basel, Basel, Switzerland.


Story Source:

The above story is based on materials provided by Children's Hospital Boston. Note: Materials may be edited for content and length.


Journal Reference:

  1. Markus Frank et al. Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells. Cancer Research, January 12, 2010

Cite This Page:

Children's Hospital Boston. "Melanoma stem cells' evasive talents." ScienceDaily. ScienceDaily, 13 January 2010. <www.sciencedaily.com/releases/2010/01/100112144220.htm>.
Children's Hospital Boston. (2010, January 13). Melanoma stem cells' evasive talents. ScienceDaily. Retrieved October 22, 2014 from www.sciencedaily.com/releases/2010/01/100112144220.htm
Children's Hospital Boston. "Melanoma stem cells' evasive talents." ScienceDaily. www.sciencedaily.com/releases/2010/01/100112144220.htm (accessed October 22, 2014).

Share This



More Health & Medicine News

Wednesday, October 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins